JP2018510650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510650A5 JP2018510650A5 JP2017560883A JP2017560883A JP2018510650A5 JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5 JP 2017560883 A JP2017560883 A JP 2017560883A JP 2017560883 A JP2017560883 A JP 2017560883A JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- cells
- cmv vector
- vector
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213267A JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114203P | 2015-02-10 | 2015-02-10 | |
| US62/114,203 | 2015-02-10 | ||
| US201562196520P | 2015-07-24 | 2015-07-24 | |
| US62/196,520 | 2015-07-24 | ||
| US201562220703P | 2015-09-18 | 2015-09-18 | |
| US62/220,703 | 2015-09-18 | ||
| PCT/US2016/017373 WO2016130693A1 (en) | 2015-02-10 | 2016-02-10 | Methods and compositions useful in generating non canonical cd8+ t cell responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Division JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510650A JP2018510650A (ja) | 2018-04-19 |
| JP2018510650A5 true JP2018510650A5 (https=) | 2019-03-22 |
| JP6816031B2 JP6816031B2 (ja) | 2021-01-20 |
Family
ID=56615684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560883A Expired - Fee Related JP6816031B2 (ja) | 2015-02-10 | 2016-02-10 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180298404A1 (https=) |
| EP (2) | EP4036239A1 (https=) |
| JP (3) | JP6816031B2 (https=) |
| KR (1) | KR20170136512A (https=) |
| CN (2) | CN108064304A (https=) |
| AU (1) | AU2016219317A1 (https=) |
| BR (1) | BR112017017092A2 (https=) |
| CA (1) | CA2976245A1 (https=) |
| EA (1) | EA201791806A1 (https=) |
| HK (2) | HK1254041A1 (https=) |
| IL (1) | IL253935B (https=) |
| MA (1) | MA41756A (https=) |
| MX (1) | MX2017010027A (https=) |
| SG (1) | SG11201706454VA (https=) |
| WO (1) | WO2016130693A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP6483033B2 (ja) | 2013-03-05 | 2019-03-13 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ | Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| AU2016355468B2 (en) | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| ES3000183T3 (en) * | 2018-09-10 | 2025-02-27 | Atara Biotherapeutics Inc | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020188111A1 (en) * | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| CN110055228B (zh) * | 2019-04-17 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 用于乙肝病毒感染的重组巨细胞病毒与应用 |
| JP2022536122A (ja) * | 2019-06-07 | 2022-08-12 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 腫瘍関連抗原特異的ｔ細胞応答 |
| AU2020334061A1 (en) * | 2019-08-20 | 2022-03-10 | Oregon Health & Science University | Modulation of T cell responses by UL18 of human cytomegalovirus |
| EP4021923A1 (en) | 2019-08-29 | 2022-07-06 | VIR Biotechnology, Inc. | Hepatitis b virus vaccines |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023034783A1 (en) | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Tuberculosis vaccines |
| CA3226699A1 (en) | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1988010311A1 (en) | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| EP1092775A1 (en) | 1991-07-05 | 2001-04-18 | American Cyanamid Company | Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
| WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| ES2267101T3 (es) | 1994-04-29 | 2007-03-01 | PHARMACIA & UPJOHN COMPANY LLC | Vacuna contra virus de inmunodeficiencia felina. |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| ATE324435T1 (de) | 1995-02-21 | 2006-05-15 | Cantab Pharmaceuticals Res Ltd | Virale zubereitungen, vektoren, immunogene und impfstoffe |
| EP0820311A4 (en) | 1995-04-04 | 2002-09-25 | Cell Genesys Inc | TRANSPLANTATION OF GENETICALLY MODIFIED CELLS WITH LOW CLASS I PROTEIN RATES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX ON THEIR SURFACE |
| EP0966301B1 (en) | 1996-07-31 | 2005-02-09 | Ortho-McNeil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| AU3910097A (en) | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| AU2002247733B2 (en) | 2001-02-21 | 2007-12-13 | The Wistar Institute Of Anatomy And Biology | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| EP1799255A4 (en) | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| AU2006284756B2 (en) | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| US8883995B2 (en) | 2009-03-06 | 2014-11-11 | Icahn School Of Medicine At Mount Sinai | Live attenuated influenza virus vaccines comprising microRNA response elements |
| WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
| CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| ES2679245T3 (es) | 2010-05-05 | 2018-08-23 | Sirion Biotech Gmbh | Vacuna contra la infección por beta-herpesvirus y uso de la misma |
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP6483033B2 (ja) | 2013-03-05 | 2019-03-13 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ | Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター |
| KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| AU2016355468B2 (en) | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
-
2016
- 2016-02-10 JP JP2017560883A patent/JP6816031B2/ja not_active Expired - Fee Related
- 2016-02-10 MA MA041756A patent/MA41756A/fr unknown
- 2016-02-10 AU AU2016219317A patent/AU2016219317A1/en not_active Abandoned
- 2016-02-10 EA EA201791806A patent/EA201791806A1/ru unknown
- 2016-02-10 CA CA2976245A patent/CA2976245A1/en not_active Abandoned
- 2016-02-10 HK HK18113013.6A patent/HK1254041A1/zh unknown
- 2016-02-10 WO PCT/US2016/017373 patent/WO2016130693A1/en not_active Ceased
- 2016-02-10 CN CN201680014682.9A patent/CN108064304A/zh active Pending
- 2016-02-10 CN CN202111437865.0A patent/CN114317611A/zh active Pending
- 2016-02-10 US US15/549,814 patent/US20180298404A1/en not_active Abandoned
- 2016-02-10 KR KR1020177025544A patent/KR20170136512A/ko not_active Ceased
- 2016-02-10 BR BR112017017092A patent/BR112017017092A2/pt not_active Application Discontinuation
- 2016-02-10 HK HK18106974.7A patent/HK1247638A1/zh unknown
- 2016-02-10 EP EP21205026.4A patent/EP4036239A1/en not_active Withdrawn
- 2016-02-10 SG SG11201706454VA patent/SG11201706454VA/en unknown
- 2016-02-10 EP EP16749813.8A patent/EP3256595A4/en not_active Withdrawn
- 2016-02-10 MX MX2017010027A patent/MX2017010027A/es unknown
-
2017
- 2017-08-09 IL IL253935A patent/IL253935B/en unknown
-
2020
- 2020-01-09 US US16/738,178 patent/US11091779B2/en not_active Expired - Fee Related
- 2020-12-23 JP JP2020213267A patent/JP2021121185A/ja active Pending
-
2022
- 2022-08-08 JP JP2022126096A patent/JP2022166122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510650A5 (https=) | ||
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| O’Hara et al. | Memory T cell inflation: understanding cause and effect | |
| Khanna et al. | Human cytomegalovirus vaccine: time to look for alternative options | |
| Schleiss et al. | Progress toward development of a vaccine against congenital cytomegalovirus infection | |
| van Zyl et al. | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice | |
| Sung et al. | Update on the current status of cytomegalovirus vaccines | |
| Hanley et al. | Controlling cytomegalovirus: helping the immune system take the lead | |
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| Griffiths et al. | Desirability and feasibility of a vaccine against cytomegalovirus | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| Farrington et al. | Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| Schermuly et al. | In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus | |
| Dasari et al. | Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases | |
| Dubensky Jr et al. | Delivery systems for gene-based vaccines | |
| JP2019502371A5 (https=) | ||
| JP2019531745A5 (https=) | ||
| Full et al. | T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor | |
| JP2021036882A5 (https=) | ||
| Hu et al. | Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development | |
| Pourchet et al. | CD8+ T-cell immune evasion enables oncolytic virus immunotherapy | |
| Khan et al. | Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes | |
| Quinn et al. | Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector | |
| Abdelaziz et al. | Development of a human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected viral block of MHC class I antigen presentation |